TOKYO--()--Stroke, the destruction of brain tissue from blockage or rupture of blood vessels, is one of the leading causes of death and permanent disability in the world. Stroke is also a common problem in Asian countries being second only to heart attack as a cause of death. Preliminary studies suggest that the main risk factors for stroke in Asian countries are undiagnosed or untreated high blood pressure (hypertension), abnormally elevated blood sugar (diabetes), smoking and elevated cholesterol. Recent information indicates that these same risk factors for stroke also damage memory and predispose to Alzheimer’s disease in the elderly.
To discuss these advances and to interchange experiences in stroke management in several Asian countries the First Asia-Pacific Symposium on Stroke have met in Tokyo (Japan) on September 13th , 2012, at the Hilton Shinjuku hotel, under the aegis of Ferrer Group (Barcelona, Spain), within the frame of the Asia-Pacific Stroke Conference (Tokyo, September 10th to 12th) Distinguished speakers and physicians from India, Philippines, South Korea, Vietnam, Thailand and Myanmar have had an opportunity to participate in this meeting, the first of its class in the Asian countries. The discussion was conducted by the international expert in the field of stroke Prof. Gustavo Román, Professor of Neurology and the Jack S. Blanton Distinguished Endowed Chair, Director Nantz National Alzheimer Center at the Methodist Neurological Institute in Houston, Texas, USA. Prof. Román is an international authority in the study of the link between stroke and Alzheimer’s disease, as well as in the epidemiology of stroke and dementia prevention.
Founded in 1959, Ferrer is a privately-held Spanish pharmaceutical company, with full vertical integration from R&D to distribution. It is present in more than 90 countries, with 23 international affiliates. Ferrer is active in the pharmaceutical, health, fine chemicals and food sectors, key areas for contributing to people’s health and quality of life.
Since the beginning, Ferrer has been committed to the research and development of innovative medicinal products in its six R&D centres (four in Spain) and to a solid industrial structure, with thirteen manufacturing centres (seven in Spain). This research and manufacturing capacity covers the pharmaceutical, diagnostics, vaccines, fine chemical, food and feed sectors.
The main therapeutic areas covered by Ferrer’s pharmaceutical production are dermatology, cardiovascular, CNS, cancer, gastrointestinal, analgesics, bone metabolism, antibiotics, immunology, diagnostics, OTC and dermocosmetics.